两张王牌在手,商业化效率加速价值兑现:云顶新耀Biopharma之路按下“快进键”

健识局
Feb 11

云顶新耀集齐了两张“王炸”。2月6日,“维适平”获批上市,用于治疗对传统治疗或生物制剂应答不充分、失应答或不耐受的中度至重度活动性溃疡性结肠炎成人患者。市场预测,其峰值销售额有望突破50亿元。这是继耐赋康之后云顶新耀又一款重磅单品,将成为支撑云顶新耀百亿营收的关键“王牌”。就在维适平获批前一天,云顶新耀与麦科奥特达成战略合作,拿下一款肾病药物MT1013的独家商业化许可。云顶新耀去年就一直在强调要...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10